Personalized therapy in chronic viral hepatitis.

[1]  C. Galli,et al.  Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc. , 1993, Journal of hepatology.

[2]  M A Nowak,et al.  Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[4]  M. Shapiro,et al.  Viral clearance without destruction of infected cells during acute HBV infection. , 1999, Science.

[5]  C. Gibbs,et al.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy , 1999, Hepatology.

[6]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[7]  Alan S. Perelson,et al.  Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed , 2001, Hepatology.

[8]  Half-Life of the Duck Hepatitis B Virus Covalently Closed Circular DNA Pool In Vivo following Inhibition of Viral Replication , 2002, Journal of Virology.

[9]  M. Brunetto,et al.  Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. , 2002, Journal of hepatology.

[10]  E. Schiff,et al.  Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B , 2002, Hepatology.

[11]  A. Lok,et al.  HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. , 2002, Hepatology.

[12]  A. Neumann,et al.  The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. , 2002, Journal of hepatology.

[13]  G. Tomlinson,et al.  High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C , 2003, Hepatology.

[14]  M. Brunetto,et al.  Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. , 2003, Journal of hepatology.

[15]  Ruy M Ribeiro,et al.  Mathematical modeling of viral kinetics: a tool to understand and optimize therapy. , 2003, Clinics in liver disease.

[16]  M. Brunetto,et al.  Sustained Response to Interferon–Ribavirin Combination Therapy Predicted by a Model of Hepatitis C Virus Dynamics Using Both Hcv Rna and Alanine Aminotransferase , 2002, Antiviral therapy.

[17]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[18]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[19]  William M. Lee,et al.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.

[20]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[21]  E. Esrailian,et al.  Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. , 2004, Journal of hepatology.

[22]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[23]  A. Andriulli,et al.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. , 2005, The New England journal of medicine.

[24]  A. Hatzakis,et al.  A viral kinetic study using pegylated interferon alfa‐2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative , 2005, Hepatology.

[25]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[26]  S. Locarnini,et al.  Antiviral drug resistance: clinical consequences and molecular aspects. , 2006, Seminars in liver disease.

[27]  R. Gieschke,et al.  A Multiphase Model of the Dynamics of HBV Infection in Hbeag-Negative Patients during Pegylated Interferon-α2A, Lamivudine and Combination Therapy , 2005, Antiviral therapy.

[28]  P. Marcellin,et al.  Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy , 2006, Hepatology.

[29]  R. Andrade,et al.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. , 2006, Gastroenterology.

[30]  J. Marrero,et al.  Virologic response and resistance to adefovir in patients with chronic hepatitis B. , 2006, Journal of hepatology.

[31]  C. Mazzucco,et al.  Entecavir resistance is rare in nucleoside naïve patients with hepatitis B , 2006, Hepatology.

[32]  S. Locarnini,et al.  Cellular and virological mechanisms of HBV drug resistance. , 2006, Journal of hepatology.

[33]  A. Geretti.  Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors. , 2006, AIDS reviews.

[34]  F. Zoulim.  Antiviral therapy of chronic hepatitis B. , 2006, Antiviral research.

[35]  M. Brunetto.  Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance. , 2007, Journal of hepatology.

[36]  R. Sacco,et al.  Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. , 2007, The Journal of antimicrobial chemotherapy.

[37]  J. Pawlotsky,et al.  Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. , 2007, Journal of hepatology.

[38]  B. Bacon,et al.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. , 2007, The New England journal of medicine.

[39]  P. Marcellin,et al.  Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B , 2006, Gut.

[40]  S. Hadziyannis,et al.  Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg‐negative chronic hepatitis B , 2007, Hepatology.